Sep 21, 2026 · 5 min
Accenture gains as Novo Nordisk loses investor confidence
Novo Slides; Accenture Up; Arhaus Upgrade
The market moves reflect competing judgments about AI safety partnerships, corporate turnarounds, and leadership in obesity drugs, before the episode widens its lens to smarter cities.
- 1Accenture rises after partnering with Anthropic to test advanced AI model safety amid concerns development is moving too quickly.
- 2Arhaus gains after Jefferies upgrades the furniture retailer, citing digital marketing, customer expansion, and a higher price target.
- 3Novo Nordisk falls as investors demand clearer turnaround evidence and worry Eli Lilly has taken the lead in obesity drugs.
Don't miss
Novo Nordisk’s promised new blockbusters fail to reassure investors, who remain focused on its lost leadership to Eli Lilly in obesity drugs.
The brief
Accenture shares rise after a partnership with Anthropic to test advanced AI model safety, placing the move against worries that development is accelerating too quickly.
Arhaus gains after Jefferies upgrades the furniture retailer to buy, with digital marketing, customer expansion, and a revised price target shaping the case.
Novo Nordisk takes the opposite path: investors remain unconvinced by promised blockbuster medicines and a turnaround plan shadowed by Eli Lilly’s obesity-drug lead.
The episode then shifts from market signals to urban systems, asking how AI, infrastructure innovation, and long-term planning can help rapidly growing cities such as Dubai.
Rohit Krishnan and Estefanía Tapias frame smart cities as an exercise in applying AI to growth, while Dubai supplies the discussion’s practical blueprint.
What was said on this episode
4 statements · 2 positive · 2 negative
Arhaus is likely to return to profitability as marketing and customer expansion efforts increase.
“An analyst says it is likely to break back into the green as it ramps up its digital marketing and other efforts to expand its customer base.”
Listen at 1:30
Novo Nordisk disappointed investors with its turnaround plans.
“Novo Nordisk. Disappointing investors here.”
Listen at 2:22
Novo Nordisk quickly lost its GLP-1 market lead to Eli Lilly.
“it quickly lost its lead. to Eli Lilly.”
Listen at 2:31
AI will accelerate processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 3:40
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Mentioned
Books & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.